Emerging BioTalk
  • Home
  • About Us
  • Contact
  • Search
  • Menu

Covid-19 Impact on Bioprocessing: PART 3 Long-term Changes Resulting from the Pandemic

October 29, 2020/in Uncategorized /by Multiple Authors

The views and opinions expressed in this blog / article are those of the authors and do not necessarily reflect the official policy or position of any other agency, organization, employer or company. Merck KGaA, Darmstadt, Germany and its Affiliates shall not be liable for any errors, omissions or delays in the information, or damage arising from its display or use. All information is provided on an as-is basis.

Introduction

We follow up our Parts 1 and 2 discussion of the impact of Covid-19 on bioprocessing, based on our recent White Paper that is also included in our research, (see www.bioplanassociates.com/17th). We interviewed major biopharmaceutical industry senior bioprocessing decision-makers, and bioprocessing suppliers in the US and Europe. The long-term effects on the biopharma and bioprocessing industry will likely impact emerging (smaller) biopharma companies and suppliers in similar ways.  For example, greater outsourcing will likely increase the number and size of projects for the larger Contract Manufacturing Organizations’. But it will also create opportunities for smaller, and niche CMOs.  Below we summarize Fig 1, describing the long-term impact of Covid-19 on bioprocessing and the industry.

Long-term effects:

  • More outsourcing 70%
  • Supply Chain Changes 60% (Demands on suppliers, ‘2nd source’)
  • “Regionalization,” 50% of developer and 46% suppliers. (More facilities, suppliers, countries, often ‘domestically’.)
  • “SUS supply crunch,” 50% of developers & 35% of suppliers, …worsening of current shortages

Supply Chain Shifts

A majority of biopharmas expect to see significant changes in their supply chain.  This will involve more supply chain security, greater transparency with their raw materials vendors (sourcing of raw materials), and other second-sourcing activities that may result in opportunities for smaller companies, to the risk and detriment of larger suppliers.

Supply chains have proven reasonably robust and deliveries of bioprocessing-related supplies manufacturing and services have continued largely unaffected worldwide.  In certain situations, manufacturing is being ramped-up in response to increased demand. At present, neither equipment nor biologics manufacturers report any significant supply chain issues, as their suppliers continue essential operations. Access to information and supply chain transparency has become more critical. Deliveries of supplies of goods and services to biopharmaceutical developer, services and supplies companies have largely continued unaffected.

The pandemic will result in more product, supplies and services companies exercising more control over their supply chains, including reaching further upstream to more suppliers. Having control of supply chains will be even more critical to maintain access to needed supplies. This will also be required to support product quality, regulatory documentation, and patient safety. Companies will be pressing suppliers (and their suppliers, on up the supply chain) for more information; and organizing this will be a challenge. Because there are relatively few suppliers of bioprocessing goods and services, there may be a need to centrally compile and facilitate access to product and regulatory documentation and information, at least regarding commonly used equipment and reagents.

Other Shifting Areas

  • R&D/pipelines: Overall, developer R&D and pipelines are expected to change little, other than adding more pandemic- and infectious disease-related R&D, while some other projects are delayed or dropped. The ‘inertia’ built into bio/pharma pipeline projects makes it difficult to pivot on projects quickly, so current pipelines are not expected to change much in the near-term, other than new vaccine and therapeutics projects.
  • Disaster Planning: Essentially all companies are working aggressively to upgrade their contingency and disaster planning. This now will include scenarios where numbers of critical staff are not working for periods of time. Worst case scenarios are no longer confined to fires, earthquakes, floods, blackouts, IT hacking, etc. These concerns will extend into the next year, as many decision-makers are worried about staffing challenges this winter, with the annual influenza epidemic overlapping the Covid-19 pandemic. Many facilities are stockpiling more PPE supplies as well.
  • More Facilities: Even at this early point in the crisis, we see that there will easily be $15-20 billion or more invested in new pandemic-related vaccines and therapeutics by governments and philanthropies, e.g., the Gate’s and Wellcome Foundations. Likely half or more of this funding will go to new manufacturing facilities. Already, multiple vaccine developers are preparing to rapidly develop capacity for production of billions of doses/year, often ‘at risk,’ building facilities even before clinical trial results are available.
  • More Modular facilities: Many new pandemic-related vaccines and biotherapeutics facilities will likely be modular. Modular units, along with SUS, will facilitate rapid cloning of facilities worldwide. Modular facilities manufacturers are already experiencing high demand, and this is likely to continue.  This trend has been accelerating for at least 5 years; the crisis will precipitate more rapid expansion.
  • More Staffing Difficulties: Chronic staffing challenges have plagued the industry for 15 years. These will now be exacerbated by the expected increase in bioprocessing for pandemic-related products. Hiring challenges and shortages of staff with expertise and experience (documented in BioPlan’s annual survey) will accelerate. Pandemic R&D and manufacturing will compete for limited staff with the rapidly growing cellular and gene therapies sectors, as new facilities come online. Expect bioprocessing expertise and even technicians to be increasingly in short supply, with recruiting more difficult and salaries increasing.

Conclusions

Changes in the bio/pharmaceutical industry are being accelerated and catalyzed by the responses to the current Covid-19 pandemic. Although suppliers have proven themselves rather robust in their dealing with the pandemic, and business is continuing generally uninterrupted, there will be significant changes. Ongoing and accelerating trends will result in changes including improved strategies to moderate future pandemics and supply disruptions, development of collaborative relationships in R&D and among suppliers, and the implementation of more rapid, flexible, and modular production processes to speed products to the market. Along with much rapid expansion in bioprocessing capacity, these changes will affect manufacturing long after the current crisis resolves.

  • Author
  • Recent Posts
Eric Langer
Eric Langer
President and Managing Partner at BioPlan Associates, Inc.
Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing,” and many other industry reports.
www.bioplanassociates.com
Eric Langer
Latest posts by Eric Langer (see all)
  • Hiring Challenges in Bioprocessing for Start-ups - May 13, 2020
  • Author
  • Recent Posts
Kamna Jhamb
Dr. Kamna Jhamb is a life sciences and healthcare market researcher. With a PhD in Biotechnology/Microbiology, she has extensive experience working in several key industry segments, and has experience at the Lawrence Berkeley National Lab (LBNL), Berkeley, CA and elsewhere. Her expertise lies in primary and secondary research, and market analysis of healthcare and biopharma segments. She contributes to international publications and journals, and researches for in-depth reports, analyses and strategic White Papers.
Latest posts by Kamna Jhamb (see all)
    • Author
    • Recent Posts
    Ronald Rader
    Ronald Rader
    Ronald A. Rader is the Senior Director, Technical Research, BioPlan Associates.He has 35+ years’ experience as a biotechnology and pharmaceutical, particularly biopharmaceutical, information specialist, analyst and publisher, and has been responsible for the Antiviral Agents Bulletin periodical; Federal Bio-Technology Transfer Directory; BIOPHARMA:Biopharmaceutical Products in the U.S. and European Market; and the Biosimilars/Biobetters Pipeline Directory
    Ronald Rader
    Latest posts by Ronald Rader (see all)
      +1
      Share this entry
      • Share on Facebook
      • Share on Twitter
      • Share on LinkedIn
      • Share by Mail
      http://emergingbiotalk.com/wp-content/uploads/2020/10/GettyImages-843765314-scaled.jpg 1707 2560 Multiple Authors http://emergingbiotalk.com/wp-content/uploads/2020/05/emergingbiotalk-header.png Multiple Authors2020-10-29 14:41:502021-01-19 10:27:11Covid-19 Impact on Bioprocessing: PART 3 Long-term Changes Resulting from the Pandemic

      Biotech Resource Hub >>

      • SUBSCRIBE TO OUR BLOG
      • SUBMIT YOUR BLOG POST

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar

      Archives

      • February 2023
      • January 2023
      • December 2022
      • November 2022
      • October 2022
      • September 2022
      • August 2022
      • July 2022
      • May 2022
      • April 2022
      • March 2022
      • February 2022
      • January 2022
      • November 2021
      • October 2021
      • September 2021
      • August 2021
      • July 2021
      • June 2021
      • May 2021
      • April 2021
      • March 2021
      • February 2021
      • January 2021
      • December 2020
      • November 2020
      • October 2020
      • September 2020
      • August 2020
      • July 2020
      • May 2020
      • April 2020
      • SUBSCRIBE TO OUR BLOG
      • SUBMIT YOUR BLOG POST

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar

      Archives

      • February 2023
      • January 2023
      • December 2022
      • November 2022
      • October 2022
      • September 2022
      • August 2022
      • July 2022
      • May 2022
      • April 2022
      • March 2022
      • February 2022
      • January 2022
      • November 2021
      • October 2021
      • September 2021
      • August 2021
      • July 2021
      • June 2021
      • May 2021
      • April 2021
      • March 2021
      • February 2021
      • January 2021
      • December 2020
      • November 2020
      • October 2020
      • September 2020
      • August 2020
      • July 2020
      • May 2020
      • April 2020

      Tags

      applications bioprocessing biotech blazar Congratulations Content education Europe FDA Format gene therapy grant grants Investigator's Brochure molecule new NGS Pharmaceuticals program services symposia tags things Tone VAR2 viral assurance viral clearance virus virus detection winner

      Business Hours

      Our support Hotline is available 24 Hours a day: (555) 343 456 7891

      • Monday-Friday: 9am to 5pm
      • Saturday: 10am to 2pm
      • Sunday: Closed

      Latest News

      • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
      • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
      • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am
      • The Future of BiopharmaDecember 6, 2022 - 4:39 am
      • Last chance: 3rd Annual Startup Symposium – Day 3November 10, 2022 - 5:39 am
      • The Lack of Funding for Women Entrepreneurs Doesn’t Stop Them from Launching – But We Still Have a Long Way to Go – And We Can Help Each Other. Assurea is ROOTING FOR YOU!October 21, 2022 - 8:27 am

      Categories

      • Bioprocessing
      • Biosafety Testing
      • End-to-End Solutions
      • Frontpage Article
      • Gene Therapy
      • Investigator's Brochure
      • News
      • Uncategorized
      • Vaccines
      • Viral Vectors
      • Webinar
      • Author
      • Recent Posts
      Ronald Rader
      Ronald Rader
      Ronald A. Rader is the Senior Director, Technical Research, BioPlan Associates.He has 35+ years’ experience as a biotechnology and pharmaceutical, particularly biopharmaceutical, information specialist, analyst and publisher, and has been responsible for the Antiviral Agents Bulletin periodical; Federal Bio-Technology Transfer Directory; BIOPHARMA:Biopharmaceutical Products in the U.S. and European Market; and the Biosimilars/Biobetters Pipeline Directory
      Ronald Rader
      Latest posts by Ronald Rader (see all)
        +1
        © 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. | Privacy Policy | Cookie Settings
        Covid-19 Impact on Bioprocessing: PART 2 Fears to Be Addressed due to Covid... Virtual ADC & Bioconjugation Symposium – December 2-3, 2020
        Scroll to top

        This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. We use cookies in our website to give you the most relevant experience. By clicking or navigating the site, you are accepting the use of all our cookies according to our Cookie Policy / Privacy Statement. You are free to decide in the Cookie Settings which categories you would like to allow. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy

        Accept All CookiesCookie Settings

        Cookie and Privacy Settings



        Cookie Preferences

        When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about how we use and share your data, please follow this link.
        Privacy Statement

        Necessary

        Always Active
        These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

        Functional

        These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., pop-up notification choices).Changes will take effect once you reload the page.

        Targeting

        These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.

        Confirm My ChoicesAllow AllDisable All

        loading

        Please wait while you are redirected to the right page...

        Please share your location to continue.

        Check our help guide for more info.

        share your location